Metastatic Clear Cell Renal Cell Carcinoma clinical trials

Explore recruiting metastatic clear cell renal cell carcinoma clinical trials.

Recruiting metastatic clear cell renal cell carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Clear Cell Renal Cell Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Had Received Prior Systemic Therapy

Italy, Spain, Finland, Ireland, Poland, Romania +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Italy, Spain, Romania, Germany, Netherlands, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOint INhibiTor (anti PD1/PDL1).

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Kidney cancer

Sweden, France, Portugal, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Metastatic Clear Cell Renal Cell Carcinoma trials by city

Metastatic Clear Cell Renal Cell Carcinoma clinical trials

Recruiting metastatic clear cell renal cell carcinoma studies right now

Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy

IDOV-Immune for Advanced Solid Tumors